An Important Message from the IXA Council

Agnès Marie Azimzadeh, Ph.D

In Memoriam - Agnès Marie Azimzadeh, Ph.D

The International Xenotransplantation Association is deeply saddened by the recent passing of our President, Agnès Azimzadeh.

Our friend and colleague Agnès Azimzadeh, passed away on March 15, 2021, after a courageous battle with intestinal cancer. She leaves her devoted husband, Djavad; their sons Julien and Philippe, and Julien’s wife Rebecca; her parents, Simone and Bernard Isabey; and her brother Daniel Isabey. The scientific and clinical transplant communities she touched at Massachusetts General Hospital, University of Maryland, and around the world join her family in celebrating her life, and mourning her premature loss.

Highlighted Publication

COVID Vax in the Immunosuppressed: Reason for Concern
— Discomfiting results in new study

MedPage Today Op-Ed by Dorry Segev, MD, PhD - March 15, 2021
Taking care of a lot of immunosuppressed patients, one big question my Johns Hopkins colleagues and I have had throughout the pandemic has been: Will vaccines rescue them from the COVID-19 threat? Based on a new study we published today in JAMA, the answer appears to be: only for some

Journal Updates


Online First

The editors of this journal are pleased to offer electronic publication of accepted papers prior to print publication. These papers can be cited using the date of access and the unique DOI number. Any final changes in manuscripts will be made at the time of print publication and will be reflected in the final electronic version of the issue.
  • Cellular and Molecular Crosstalk of Graft Endothelial Cells During AMR: Effector Functions and Mechanisms
  • Antibody-Mediated Rejection and the Graft Endothelium in Solid Organ Transplantation
  • Casirivimab-Imdevimab for Treatment of COVID-19 in Solid Organ Transplant Recipients: an Early Experience
  • The Classification of Biliary Strictures ın Patients With Right Lobe Liver Transplant Recipients and Its Relation to Traversing the Stricture With a Guidewire
  • Recommendations and guidance on nutritional supplementation in the liver transplant setting

Hot off the Press 


Selected Publications by TTS Education Committee. This week's selection made by Drs. Enver Akalin and Marlies Reinders.

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Florian Krammer et al.
NEJM March 10, 2021. DOI: 10.1056/NEJMc2101667
This study analyzed antibody responses in 110 study participants with (n=43) or without (n=67) documented preexisting SARS-CoV-2 immunity, who received their first spike mRNA vaccine dose in 2020 (88 received the Pfizer vaccine and 22 the Moderna vaccine). The antibody titers of vaccinees with preexisting immunity were 10 to 45 times as high as those of vaccinees without preexisting immunity at the same time points after the first vaccine dose (e.g., 25 times as high at 13 to 16 days) and also exceeded the median antibody titers measured in participants without preexisting immunity after the second vaccine dose by more than a factor of 6. Although the antibody titers of the vaccinees without preexisting immunity increased by a factor of 3 after the second vaccine dose, no increase in antibody titers was observed in the Covid-19 survivors who received the second vaccine dose.

Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2

Jim Baggen et al.
Nat Genet. 2021 Mar 8. doi: 10.1038/s41588-021-00805-2.
This study discovered that SARS-CoV-2 requires the lysosomal protein TMEM106B to infect human cell lines and primary lung cells. TMEM106B overexpression enhanced SARS-CoV-2 infection as well as pseudovirus infection, suggesting a role in viral entry. Furthermore, single-cell RNA-sequencing of airway cells from patients with COVID-19 demonstrated that TMEM106B expression correlates with SARS-CoV-2 infection. The present study uncovered a collection of coronavirus host factors that may be exploited to develop drugs against SARS-CoV-2 infection or future zoonotic coronavirus outbreaks.

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Wilfredo F. Garcia-Beltran et al.
Cell March 8 2021,
This study evaluated the neutralization potency of 99 individuals that received one or two doses of either BNT162b2 or mRNA-1273 vaccines against pseudoviruses representing 10 globally circulating strains of SARS-CoV-2. Five of the 10 pseudoviruses, harboring receptor-binding domain mutations, including K417N/T, E484K, and N501Y, were highly resistant to neutralization. Cross-neutralization of B.1.351 variants was comparable to SARS-CoV and bat-derived WIV1- CoV, suggesting that a relatively small number of mutations can mediate potent escape from vaccine responses. While the clinical impact of neutralization resistance remains uncertain, these results highlight the potential for variants to escape from neutralizing humoral immunity and emphasize the need to develop broadly protective interventions against the evolving pandemic.

Upcoming Webinars

New Date!
Donor/Recipient Pair:

March 23, 2021

Open to all healthcare professionals

Speaker: Marcelo Cantarovich, TTS President
Moderator: Jean Tchervenkov, Montreal, Canada

Free to attend

Wednesday, April 7, 2021
2:00PM - 6:00PM (İstanbul Time Zone)

The Middle East Society For Organ Transplantation (MESOT) invites you to a new webinar on How to Increase Organ Donation and Transplantation in Our Region during the Covid-19 Pandemic Period.

With COVID-19 pandemic spreading across the globe since last year, it had the immediate effect of severely reducing living and deceased organ donation and transplantation activity worldwide.

LATEST VIDEO - March 1 COVID & Vaccines Webinar is now available!




Staff Directory


The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6